Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

Abstract Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our site has initiated a study evaluating safety and efficacy of SARS-CoV-2 vaccinatio...

Full description

Bibliographic Details

Published in:	Journal of Hematology & Oncology
Main Authors:	Evangelos Terpos, Flora Zagouri, Michalis Liontos, Aimilia D. Sklirou, Konstantinos Koutsoukos, Christos Markellos, Alexandros Briasoulis, Eleni-Dimitra Papanagnou, Ioannis P. Trougakos, Meletios-Athanasios Dimopoulos
Format:	Article
Language:	English
Published:	BMC 2021-05-01
Subjects:	SARS-CoV-2 Vaccination Cancer Immune checkpoint inhibitors BNT162b2 AZD1222
Online Access:	https://doi.org/10.1186/s13045-021-01099-x